Inhibition of the plasma-aldosterone response to frusemide by bromocriptine.
The administration of the long-acting dopaminergic agonist bromocriptine to five healthy volunteers inhibited the rise in plasma-aldosterone that normally follows the administration of frusemide. This inhibition was not due to a lowering of plasma-renin activity. It is suggested that dopamine may modulate the normal secretion of aldosterone either directly, or indirectly, possible by inhibition of prolactin secretion.
D000450:Aldosterone / Q000097:blood*; D001971:Bromocriptine / Q000008:administration & dosage / Q000494:pharmacology*; D004298:Dopamine / Q000502:physiology; D004873:Ergolines / Q000494:pharmacology*; D005665:Furosemide / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007275:Injections, Intravenous; D000451:Mineralocorticoid Receptor Antagonists; D011188:Potassium / Q000652:urine; D012083:Renin / Q000097:blood / Q000378:metabolism; D012964:Sodium / Q000652:urine
D004873:Ergolines; D000451:Mineralocorticoid Receptor Antagonists; D001971:Bromocriptine; D000450:Aldosterone; D005665:Furosemide; D012964:Sodium; D012083:Renin; D011188:Potassium; D004298:Dopamine